Senior FDA Officials Just Laid Out Their New Framework for Psychedelic Drugs — in NEJM
Four senior FDA officials — Michael Davis, Teresa Buracchio, Tiffany Farchione, and Bernard Fischer — published a perspective piece in the New England Journal of Medicine on Sept 9-10 laying out how the agency plans to actually evaluate psychedelic drugs, days ahead of today's public hearing on the topic. The piece confronts the field's core methodology problem directly: functional unblinding rates in psilocybin trials routinely exceed 80%, since it's hard to hide from a patient (or their clinician) that they just took a psychedelic. Rather than pretending the standard placebo-controlled model works here, the framework proposes active-placebo conditions, measuring patient expectancy at baseline, and statistical models that treat the therapeutic alliance itself as a variable to control for — not just accept as noise. It follows the FDA's finalized clinical-trial guidance from July and sets up the terms for today's hearing, where the agency is expected to hear public input on exactly these design questions.
Read at Psychedelic Alpha